免疫系统
微生物学
生物
病毒
结核分枝杆菌
没食子酸表没食子酸酯
免疫增强剂
病毒学
免疫学
肺结核
医学
多酚
抗氧化剂
生物化学
病理
作者
Zijuan Zhao,Meiyan Feng,Juan Wan,Xin Zheng,Cuiqin Teng,Xinya Xie,Wenjing Pan,Baozhu Hu,Jianan Huang,Liu Z,Jian Wu,Shuxian Cai
出处
期刊:Food & Function
[The Royal Society of Chemistry]
日期:2021-01-01
卷期号:12 (20): 9607-9619
被引量:25
摘要
At the end of 2019, the COVID-19 virus spread worldwide, infecting millions of people. Infectious diseases induced by pathogenic microorganisms such as the influenza virus, hepatitis virus, and Mycobacterium tuberculosis are also a major threat to public health. The high mortality caused by infectious pathogenic microorganisms is due to their strong virulence, which leads to the excessive counterattack by the host immune system and severe inflammatory damage of the immune system. This paper reviews the efficacy, mechanism and related immune regulation of epigallocatechin-3-gallate (EGCG) as an anti-pathogenic microorganism drug. EGCG mainly shows both direct and indirect anti-infection effects. EGCG directly inhibits early infection by interfering with the adsorption on host cells, inhibiting virus replication and reducing bacterial biofilm formation and toxin release; EGCG indirectly inhibits infection by regulating immune inflammation and antioxidation. At the same time, we reviewed the bioavailability and safety of EGCG in vivo. At present, the bioavailability of EGCG can be improved to some extent using nanostructured drug delivery systems and molecular modification technology in combination with other drugs. This study provides a theoretical basis for the development of EGCG as an adjuvant drug for anti-pathogenic microorganisms.
科研通智能强力驱动
Strongly Powered by AbleSci AI